Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
2024年9月12日 - 9:00PM
ビジネスワイヤ（英語）
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced agenda topics and speakers
for its upcoming Investor & Analyst Day on Friday, September 20
from 9:00 a.m. to 12:00 p.m. ET in New York.
The event will feature presentations from Marinus’ leadership
and key opinion leaders (KOLs) with a focus on the development
program and commercial launch preparations for ZTALMY® (ganaxolone)
oral suspension CV in tuberous sclerosis complex (TSC). Marinus’
leadership will provide updated baseline patient demographics and
characteristics from the Phase 3 TrustTSC trial and discuss the
market opportunity in TSC. KOLs will share their clinical
experiences with TSC, present new open label extension data from
Marinus’ Phase 2 TSC clinical trial, and provide an overview on the
burden of illness, current treatment landscape, and limitations. In
addition, Marinus’ leadership will highlight how the Company is
planning to expand its clinical pipeline with development programs
in other neurodevelopmental epilepsies, pending the results of the
TrustTSC trial which is expected to readout topline data in the
first half of the fourth quarter of 2024.
Marinus Speakers:
- Scott Braunstein, M.D., Chairman of the Board and Chief
Executive Officer
- Steven E. Pfanstiel, Chief Financial Officer and Chief
Operating Officer
- Joseph Hulihan, M.D., Chief Medical Officer
- Christy Shafer, Chief Commercial Officer
- Alex Aimetti, Ph.D., Chief Scientific Officer
- Sonya Weigle, Chief People and Investor Relations Officer
- Lisa Lejuwaan, Senior Vice President and Business Unit Lead,
Rare Genetic Epilepsy
KOL Speakers:
- Dr. Mary Kay Koenig, M.D., Director of the Center for Treatment
of Pediatric Neurodegenerative Disease (CTPND), Director of
Research for the Division of Child and Adolescent Neurology at the
University of Texas McGovern Medical School
- Dr. Rajsekar R. Rajaraman, M.D., M.S., Director of the UCLA
Tuberous Sclerosis Center of Excellence and the UCLA CDKL5 Center
of Excellence, Associate Professor in Pediatric Neurology at UCLA
Mattel Children's Hospital
In-person attendance is open to invited research analysts and
institutional investors. All others are invited to watch the live
video webcast. Live questions will be taken by in-person guests,
and virtual participants may submit questions through the webcast
platform.
To register for the video webcast, please visit the Investor
Relations section of the Company's website at
https://ir.marinuspharma.com/events-and-presentations/. A replay of
the webcast will be archived on the Investor Relations section of
the Company's website following the event.
Featured KOL Speaker Biographies: Dr. Mary Kay Koenig
serves as the Director of the CTPND and Director of Research for
the Division of Child & Adolescent Neurology at the University
of Texas McGovern Medical School. Dr. Koenig attended the
University of Texas in Austin where she received a Bachelor of Arts
in Biochemistry. Following undergraduate school, Dr. Koenig
received a Master's of Science in Microbiology at Southwest Texas
State University followed by her Medical Doctorate at St. George’s
School of Medicine. After medical school, Dr. Koenig completed a
pediatrics residency at the University of Texas Medical Branch in
Galveston and a fellowship in Child and Adolescent Neurology at The
University of Texas Medical School. Upon completion of her
fellowship, she joined the faculty and is now a tenured professor.
She has served as the director for the UT Mitochondrial Center of
Excellence since 2007, the co-Director for the UT Memorial Hermann
Tuberous Sclerosis Clinic since 2007, and the Leigh Syndrome clinic
director since 2013. Dr. Koenig strives to provide excellent clinic
care and advance research for children afflicted with genetic
neurodegenerative disease. She also works to mentor and educate
junior faculty, fellows, residents, and medical students in the art
of medicine and clinical research.
Dr. Rajsekar "Raj" Rajaraman is an Associate Professor in
Pediatric Neurology at the UCLA Mattel Children's Hospital. He
completed his Pediatric Neurology residency, Clinical
Neurophysiology fellowship, and Epilepsy fellowship training at
UCLA. A native of New Jersey, Dr. Rajaraman completed his
pediatrics residency at the Unterberg Children's Hospital at
Monmouth Medical Center in New Jersey. During his pediatric
residency, his exposure to seizures and the effects that epilepsy
has on the patient and family led to him pursuing a career in
pediatric epileptology at UCLA. Currently, his clinical and
research interests involve all aspects of infantile spasms, as well
as its effects in Tuberous Sclerosis and CDKL5 Deficiency Disorder.
Dr. Rajaraman is currently the Director of the UCLA Tuberous
Sclerosis Center of Excellence as well as the UCLA CDKL5 Center of
Excellence. He is the primary investigator of over a dozen
pharmaceutical and investigator driven clinical trials and studies.
He has presented research at multiple conferences, including the
American Academy of Neurology, Child Neurology Society, and the
American Epilepsy Society, receiving achievements including the
national 2014 American Epilepsy Society Young Investigator Award.
Dr. Rajaraman has multiple publications on rare developmental
epileptic encephalopathies (DEE). In addition to his clinical and
research interests, Dr. Rajaraman is an active member of the
American Academy of Neurology (AAN) and American Epilepsy Society
(AES). He volunteers for the Epilepsy Foundation of Greater Los
Angeles, including helping at their annual Walk to End Epilepsy at
the Rose Bowl, as well as the Epilepsy Awareness Day at
Disneyland.
About Marinus Pharmaceuticals Marinus is a
commercial-stage pharmaceutical company dedicated to the
development of innovative therapeutics for seizure disorders. The
Company’s product, ZTALMY ® (ganaxolone) oral suspension CV, is an
FDA-approved prescription medication introduced in the U.S. in
2022. For more information, please visit www.marinuspharma.com and
follow us on Facebook, LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240912377218/en/
Investors Sonya Weigle Chief People
and Investor Relations Officer Marinus Pharmaceuticals, Inc.
sweigle@marinuspharma.com
Media Molly Cameron Director,
Corporate Communications & Investor Relations Marinus
Pharmaceuticals, Inc. mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
過去 株価チャート
から 10 2024 まで 11 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
過去 株価チャート
から 11 2023 まで 11 2024
